Circulating and tumor-infiltrating Foxp3+ regulatory T cell subset in chinese patients with extranodal NK/T cell lymphoma

International Journal of Biological Sciences

Volumn 7, Issue 7, 2011, Pages 1027-1036

  Peng, Rou Jun ^a   Huang, Zhou Feng ^a   Zhang, Yi Lan ^a   Yuan, Zhong Yu ^a   Xia, Yi ^a   Jiang, Wen Qi ^a   Zeng, Yi Xin ^a   Li, Jiang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

EBV; Extranodal Nk T cell lymphoma; Tumor infiltrating lym phocytes

Indexed keywords

HUMAN HERPESVIRUS 4;

EID: 80052707915     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7.1027     Document Type: Article

References (34)

1. Harris NL, Jaffe ES, Diebold J et al. The World Health Organi-zation classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Com-mittee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419-1432.
2. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. France: In-ternational Agency for Research on Cancer. 2008.
3. Hsieh PP, Tung CL, Chan AB et al. EBV viral load in tumor tissue is an important prognostic indicator for nasal NK/T-cell lymphoma. Am J Clin Pathol 2007; 128: 579-584.
4. Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
5. Miotto D, Cascio NL, Stendardo M et al. CD8+ T cells express-ing IL-10 are associated with a favourable prognosis in lung cancer. Lung Cancer 2010; 69: 355-360.
6. Sorbye SW, Kilvaer T, Valkov A et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 2011; 6: e14611.
7. Suzuki H, Chikazawa N, Tasaka T et al. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 2010; 59: 653-661.
8. Zhang YL, Li J, Mo HY et al. Different subsets of tumor infil-trating lymphocytes correlate with NPC progression in differ-ent ways. Mol Cancer 2010; 9: 4.
9. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188: 2199-2204.
10. Wolf AM, Rumpold H, Wolf D et al. Role of forkhead box pro-tein 3 expression in invasive breast cancer. J Clin Oncol 2007; 25: 4499-4500.
11. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regu-latory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
12. Salama P, Phillips M, Grieu F et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colo-rectal cancer. J Clin Oncol 2009; 27: 186-192.
13. Alvaro T, Lejeune M, Salvado MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompany-ing cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467-1473.
14. Tzankov A, Meier C, Hirschmann P et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with im-proved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lym-phoma. Haematologica 2008; 93: 193-200.
15. Huang JJ, Jiang WQ, Lin TY et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 2011; 22: 149-155.
16. Wang HY, Peng G, Guo Z et al. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by anti-gen-specific CD4+ regulatory T cells. J Immunol 2005; 174: 2661-2670.
17. Kong QL, Hu LJ, Cao JY et al. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and in-creases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 2010; 6: e1000940.
18. Trzonkowski P, Szmit E, Mysliwska J, Mysliwski A. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clin Immunol 2006; 119: 307-316.
19. Li J, Qian CN, Zeng YX. Regulatory T cells and EBV associated malignancies. Int Immunopharmacol 2009; 9: 590-592.
20. Jones K, Gandhi MK. Epstein-Barr virus DNA as a biomarker for Epstein-Barr virus-positive lymphomas: are we there yet? Leuk Lymphoma 2009; 50: 684-686.
21. Wolf AM, Wolf D, Steurer M et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606-612.
22. Shen LS, Wang J, Shen DF et al. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 2009; 131: 109-118.
23. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008; 14: 5166-5172.
24. Meloni F, Morosini M, Solari N et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006; 67: 1-12.
25. Hippocrate A, Oussaief L, Joab I. Possible role of EBV in breast cancer and other unusually EBV-associated cancers. Cancer Lett 2011; 305: 144-149.
26. Peh SC, Kim LH, Poppema S. Frequent presence of subtype A virus in Epstein-Barr virus-associated malignancies. Pathology 2002; 34: 446-450.
27. Rickinson AB. Immune intervention against virus-associated human cancers. Ann Oncol 1995; 6 (Suppl 1): 69-71.
28. Cevenini R, Donati M, Moroni A et al. Specific Epstein-Barr virus serological response in patients with nasopharyngeal carcinoma detected by immunoblotting. Eur J Epidemiol 1988; 4: 301-305.
29. Rickinson AB, Gregory CD, Young LS. Viruses and cancer risks: outgrowth of Epstein-Barr virus-positive Burkitt's lymphoma in the immune host. Med Oncol Tumor Pharmacother 1987; 4: 177-186.
30. Houston KJ, Blasecki JW. Assessment of host immune status during progressive growth and after excision of DNA virus (simian virus 40) tumors in hamsters: comparison of tu-mor-specific and tumor-unrelated parameters of immune re-sponsiveness. J Natl Cancer Inst 1979; 63: 665-673.
31. Bowen JM, Dmochowski L, Miller MF et al. Implications of humoral antibody in mice and humans to breast tumor and mouse mammary tumor virus-associated antigens. Cancer Res 1976; 36: 759-764.
32. Wang RF. Immune suppression by tumor-specific CD4+ regu-latory T-cells in cancer. Semin Cancer Biol 2006; 16: 73-79.
33. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20: 241-246.
34. Kim WY, Jeon YK, Kim TM et al. Increased quantity of tu-mor-infiltrating FOXP3-positive regulatory T cells is an inde-pendent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009; 20: 1688-1696.